Phaseline

Companies › Innoviva Specialty Therapeutics

Innoviva Specialty Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease; next expected readout May 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sulbactam-durlobactam
Beta-lactam antibiotic with durlobactam, a serine beta-lactamase inhibitor
–Phase 1Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)May 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06801223Sulbactam-durlobactamPhase 1Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)Infectious diseaseMay 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.